

Udaya S Tantry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6483438/publications.pdf>

Version: 2024-02-01

276

papers

16,831

citations

23567

58

h-index

16183

124

g-index

302

all docs

302

docs citations

302

times ranked

11477

citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy. JAMA - Journal of the American Medical Association, 2009, 302, 849.	7.4	1,319
2	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. Journal of the American College of Cardiology, 2010, 56, 919-933.	2.8	1,058
3	Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease. Circulation, 2009, 120, 2577-2585.	1.6	1,035
4	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. Journal of the American College of Cardiology, 2013, 62, 2261-2273.	2.8	807
5	Platelet Reactivity in Patients and Recurrent Events Post-Stenting. Journal of the American College of Cardiology, 2005, 46, 1820-1826.	2.8	628
6	Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis. Journal of the American College of Cardiology, 2005, 46, 1827-1832.	2.8	525
7	Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. Circulation, 2010, 121, 1188-1199.	1.6	419
8	Increased Risk in Patients With High Platelet Aggregation Receiving Chronic Clopidogrel Therapy Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2007, 49, 657-666.	2.8	378
9	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2019, 12, 1521-1537.	2.9	366
10	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia. Annals of Internal Medicine, 2015, 163, 40-51.	3.9	357
11	Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets. Circulation, 2005, 111, 1153-1159.	1.6	350
12	The Relation of Dosing to Clopidogrel Responsiveness and the Incidence of High Post-Treatment Platelet Aggregation in Patients Undergoing Coronary Stenting. Journal of the American College of Cardiology, 2005, 45, 1392-1396.	2.8	345
13	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering. JAMA - Journal of the American Medical Association, 2018, 319, 1566.	7.4	339
14	Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. Journal of the American College of Cardiology, 2005, 46, 1705-1709.	2.8	306
15	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. European Heart Journal, 2015, 36, 1762-1771.	2.2	297
16	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
17	Platelet Function Measurement-Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery. Circulation: Cardiovascular Interventions, 2012, 5, 261-269.	3.9	244
18	Nitric Oxide Regulates Wound Healing. Journal of Surgical Research, 1996, 63, 237-240.	1.6	243

#	ARTICLE	IF	CITATIONS
19	The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel. Journal of the American College of Cardiology, 2008, 52, 531-533.	2.8	211
20	The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients. Diabetes, 2007, 56, 3014-3019.	0.6	206
21	Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization. JAMA - Journal of the American Medical Association, 2012, 308, 1785.	7.4	200
22	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nature Reviews Cardiology, 2022, 19, 475-495.	13.7	180
23	First Analysis of the Relation Between <i>CYP2C19</i> Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. Circulation: Cardiovascular Genetics, 2010, 3, 556-566.	5.1	163
24	Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study. Journal of the American College of Cardiology, 2010, 56, 185-193.	2.8	157
25	Clopidogrel resistance?. Thrombosis Research, 2007, 120, 311-321.	1.7	151
26	Optimal Timing of Coronary Invasive Strategy in Non- ST -Segment Elevation Acute Coronary Syndromes. Annals of Internal Medicine, 2013, 158, 261.	3.9	151
27	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. Thrombosis and Haemostasis, 2021, 121, 422-432.	3.4	149
28	Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. American Heart Journal, 2010, 160, 346-354.	2.7	145
29	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thrombosis Research, 2005, 115, 89-94.	1.7	138
30	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. Platelets, 2016, 27, 642-649.	2.3	133
31	The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel. Journal of the American College of Cardiology, 2013, 62, 505-512.	2.8	128
32	Combination Antithrombotic Therapies. Circulation, 2010, 121, 569-583.	1.6	112
33	Effect of <i>CYP2C19</i> *2 and <i>CYP2C19</i> *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin. Circulation: Cardiovascular Interventions, 2011, 4, 585-594.	3.9	112
34	Platelet Function Testing and Genotyping Improve Outcome in Patients Treated With Antithrombotic Agents. Circulation, 2012, 125, 1276-1287.	1.6	111
35	Drug Insight: clopidogrel nonresponsiveness. Nature Clinical Practice Cardiovascular Medicine, 2006, 3, 387-395.	3.3	105
36	Nitric Oxide Metabolism in Wounds. Journal of Surgical Research, 1997, 71, 25-31.	1.6	103

#	ARTICLE	IF	CITATIONS
37	Nitric Oxide in the Healing Wound: A Time-Course Study. Journal of Surgical Research, 2001, 101, 104-108.	1.6	103
38	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: A potential antiplatelet therapeutic target. Platelets, 2008, 19, 595-604.	2.3	101
39	Genetic Variation in <i>PEAR1</i> Is Associated With Platelet Aggregation and Cardiovascular Outcomes. Circulation: Cardiovascular Genetics, 2013, 6, 184-192.	5.1	97
40	Intra-abdominal sepsis impairs colonic reparative collagen synthesis. American Journal of Surgery, 1996, 171, 102-108.	1.8	91
41	Genotyping. Journal of the American College of Cardiology, 2010, 56, 112-116.	2.8	90
42	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 189-197.	2.4	89
43	Effect of Clopidogrel With and Without Eptifibatide on Tumor Necrosis Factor-Alpha and C-Reactive Protein Release After Elective Stenting. Journal of the American College of Cardiology, 2006, 48, 2186-2191.	2.8	84
44	Bleeding and thrombosis associated with ventricular assist device therapy. Journal of Heart and Lung Transplantation, 2017, 36, 1164-1173.	0.6	83
45	Platelet activation in myocardial ischemic syndromes. Expert Review of Cardiovascular Therapy, 2004, 2, 535-545.	1.5	82
46	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American Heart Journal, 2011, 161, 598-604.	2.7	78
47	The Effect of St John's Wort on the Pharmacodynamic Response of Clopidogrel in Hyporesponsive Volunteers and Patients: Increased Platelet Inhibition by Enhancement of CYP3A4 Metabolic Activity. Journal of Cardiovascular Pharmacology, 2011, 57, 86-93.	1.9	77
48	Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. American Heart Journal, 2012, 164, 35-42.	2.7	77
49	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. Nature Biomedical Engineering, 2020, 4, 1188-1196.	22.5	77
50	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies. American Heart Journal, 2011, 162, 160-165.	2.7	75
51	Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic Risk Progression (TRIP) Study. Platelets, 2010, 21, 360-367.	2.3	73
52	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 989-1004.	3.3	70
53	Aspirin Resistance. Progress in Cardiovascular Diseases, 2009, 52, 141-152.	3.1	69
54	Bivalirudin and Clopidogrel With and Without Eptifibatide for Elective Stenting: Effects on Platelet Function, Thrombelastographic Indexes, and Their Relation to Periprocedural Infarction. Journal of the American College of Cardiology, 2009, 53, 648-657.	2.8	68

#	ARTICLE	IF	CITATIONS
55	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , 2019, 139, 2170-2185.	1.6	66
56	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2027-2045.	1.8	65
57	Dark Chocolate Effect on Platelet Activity, C-Reactive Protein and Lipid Profile: A Pilot Study. <i>Southern Medical Journal</i> , 2008, 101, 1203-1208.	0.7	64
58	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 437-445.	2.1	63
59	Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. <i>Wound Repair and Regeneration</i> , 2000, 8, 547-553.	3.0	60
60	G-Proteinâ€‘Coupled Receptors Signaling Pathways in New Antiplatelet Drug Development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 500-512.	2.4	60
61	Platelet-Mediated Thrombosis. <i>Circulation Research</i> , 2016, 118, 1380-1391.	4.5	56
62	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome. <i>Annals of Internal Medicine</i> , 2016, 164, 600.	3.9	55
63	Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis. <i>American Journal of Cardiology</i> , 2009, 104, 525-530.	1.6	54
64	Clopidogrel Efficacy and Cigarette Smoking Status. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2495-6.	7.4	54
65	Antiplatelet and Anticoagulant Agents in Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 1-14.	4.1	54
66	Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease. <i>Clinical Pharmacokinetics</i> , 2012, 51, 397-409.	3.5	52
67	Direct oral anticoagulants: a review on the current role and scope of reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 271-286.	2.1	52
68	Aspirin and Clopidogrel Resistance: Consideration and Management. <i>Journal of Interventional Cardiology</i> , 2006, 19, 439-448.	1.2	51
69	Assessment of clopidogrel responsiveness: Measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , 2007, 121, 107-115.	1.7	51
70	Clopidogrel and Proton Pump Inhibitors. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 365-380.	2.9	51
71	AZD6140. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 225-229.	4.1	50
72	Platelet reactivity during ticagrelor maintenance therapy: A patient-level data meta-analysis. <i>American Heart Journal</i> , 2014, 168, 530-536.	2.7	50

#	ARTICLE	IF	CITATIONS
73	Platelet function measured by VerifyNow [®] identifies generalized high platelet reactivity in aspirin treated patients. <i>Platelets</i> , 2007, 18, 414-423.	2.3	48
74	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. <i>Thrombosis Research</i> , 2007, 119, 563-570.	1.7	46
75	Effect of Long-Term Clopidogrel Treatment on Platelet Function and Inflammation in Patients Undergoing Coronary Arterial Stenting. <i>American Journal of Cardiology</i> , 2009, 103, 1546-1550.	1.6	46
76	Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 268-275.	1.0	44
77	The link between heightened thrombogenicity and inflammation: Pre-procedure characterization of the patient at high risk for recurrent events after stenting. <i>Platelets</i> , 2009, 20, 97-104.	2.3	43
78	Current Antiplatelet Treatment Strategy in Patients with Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2015, 39, 95.	4.7	40
79	Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression. <i>American Heart Journal</i> , 2008, 155, 56-61.	2.7	38
80	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. <i>European Heart Journal</i> , 2012, 33, 2151-2162.	2.2	37
81	An Initial Experiment With Personalized Antiplatelet Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1136.	7.4	36
82	Hypothesis formulation from subgroup analyses: Nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". <i>American Heart Journal</i> , 2010, 159, 744-748.	2.7	35
83	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. <i>Annals of Thoracic Surgery</i> , 2016, 102, 2010-2017.	1.3	35
84	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , 2019, 64, 166-179.	9.0	34
85	Stimulation of fibroblast proliferation and matrix contraction by wound fluid. <i>International Journal of Biochemistry and Cell Biology</i> , 1997, 29, 231-239.	2.8	33
86	Inflammatory changes during the "common cold" are associated with platelet activation and increased reactivity of platelets to agonists. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 713-718.	1.0	33
87	Omeprazole. <i>Journal of the American College of Cardiology</i> , 2008, 51, 261-263.	2.8	33
88	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1594-1596.	3.4	33
89	Sepsis Impairs Anastomotic Collagen Gene Expression and Synthesis: A Possible Role for Nitric Oxide. <i>Journal of Surgical Research</i> , 1997, 69, 81-86.	1.6	32
90	Time dependence of clopidogrel loading effect: Platelet activation versus platelet aggregation. <i>Thrombosis Research</i> , 2012, 129, 1-2.	1.7	32

#	ARTICLE	IF	CITATIONS
91	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. Expert Opinion on Pharmacotherapy, 2020, 21, 1851-1865.	1.8	32
92	Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?. Current Vascular Pharmacology, 2018, 16, 459-476.	1.7	31
93	Resistance to antiplatelet drugs: what progress has been made?. Expert Opinion on Pharmacotherapy, 2014, 15, 2553-2564.	1.8	30
94	Meta-Analysis of Direct and Indirect Comparison of Ticagrelor and Prasugrel Effects on Platelet Reactivity. American Journal of Cardiology, 2015, 115, 716-723.	1.6	30
95	Clopidogrel response variability and the advent of personalised antiplatelet therapy. Thrombosis and Haemostasis, 2011, 106, 265-271.	3.4	29
96	Peri-operative platelet function testing: The potential for reducing ischaemic and bleeding risks. Thrombosis and Haemostasis, 2011, 106, 248-252.	3.4	28
97	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. Current Medical Research and Opinion, 2014, 30, 813-828.	1.9	28
98	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. Current Heart Failure Reports, 2016, 13, 319-328.	3.3	28
99	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. Circulation, 2018, 138, 2145-2159.	1.6	28
100	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 589-597.	3.4	27
101	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. Korean Circulation Journal, 2021, 51, 202.	1.9	27
102	Controversies in Oral Antiplatelet Therapy in Patients Undergoing Aortocoronary Bypass Surgery. Annals of Thoracic Surgery, 2010, 90, 1040-1051.	1.3	26
103	Ticagrelor for the treatment of arterial thrombosis. Expert Opinion on Pharmacotherapy, 2010, 11, 2251-2259.	1.8	24
104	Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. Thrombosis and Haemostasis, 2014, 111, 713-724.	3.4	22
105	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. Journal of Thrombosis and Thrombolysis, 2019, 47, 16-30.	2.1	22
106	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. Advances in Therapy, 2021, 38, 3911-3923.	2.9	22
107	Prasugrel. Expert Opinion on Investigational Drugs, 2006, 15, 1627-1633.	4.1	21
108	Assessment of oral antithrombotic therapy by platelet function testing. Nature Reviews Cardiology, 2011, 8, 572-579.	13.7	21

#	ARTICLE	IF	CITATIONS
109	Clopidogrel Resistance: Implications for Coronary Stenting. <i>Current Pharmaceutical Design</i> , 2006, 12, 1261-1269.	1.9	20
110	Platelet reactivity and thrombogenicity in postmenopausal women. <i>Menopause</i> , 2013, 20, 57-63.	2.0	20
111	Influence of Race and Sex on Thrombogenicity in a Large Cohort of Coronary Artery Disease Patients. <i>Journal of the American Heart Association</i> , 2014, 3, e001167.	3.7	20
112	Current Options in Oral Antiplatelet Strategies During Percutaneous Coronary Interventions. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 4-13.	1.4	20
113	The platelet-related effects of tenecteplase versus alteplase versus reteplase. <i>Blood Coagulation and Fibrinolysis</i> , 2005, 16, 1-7.	1.0	19
114	Relation of Fish Oil Supplementation to Markers of Atherothrombotic Risk in Patients With Cardiovascular Disease Not Receiving Lipid-Lowering Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1204-1211.	1.6	19
115	Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1376-1386.	3.4	19
116	Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring. <i>Current Pharmaceutical Design</i> , 2013, 19, 3795-3815.	1.9	19
117	Vorapaxar: a novel protease-activated receptor-1 inhibitor. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1445-1453.	4.1	18
118	Toward a therapeutic window for antiplatelet therapy in the elderly. <i>European Heart Journal</i> , 2012, 33, 1187-1189.	2.2	18
119	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 447-462.	1.5	18
120	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2016, 118, 1941-1947.	1.6	17
121	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , 2016, 12, 45-58.	1.2	17
122	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , 2020, 29-30, 100647.	7.1	17
123	First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab274.	0.9	17
124	Clopidogrelâ€PPI interaction, an ongoing controversy. <i>Nature Reviews Cardiology</i> , 2011, 8, 7-8.	13.7	16
125	Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y ₁₂ receptor inhibitors and high on-treatment platelet reactivity. <i>Platelets</i> , 2013, 24, 166-169.	2.3	16
126	Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 911-922.	3.4	15

#	ARTICLE	IF	CITATIONS
127	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. Expert Opinion on Pharmacotherapy, 2018, 19, 653-665.	1.8	15
128	GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. Lancet, The, 2017, 389, 1773-1775.	13.7	14
129	Exploration of PCSK9 as a Cardiovascular Risk Factor. Journal of the American College of Cardiology, 2017, 70, 1463-1466.	2.8	14
130	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease – A meta-analysis. International Journal of Cardiology, 2018, 269, 292-297.	1.7	14
131	“Blueprinting” thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. Journal of Thrombosis and Thrombolysis, 2019, 47, 192-199.	2.1	14
132	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. Journal of Thrombosis and Thrombolysis, 2019, 48, 373-381.	2.1	14
133	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. Journal of Thrombosis and Thrombolysis, 2021, 51, 454-465.	2.1	14
134	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. American Heart Journal, 2013, 166, 95-103.	2.7	13
135	Vorapaxar in the secondary prevention of atherothrombosis. Expert Review of Cardiovascular Therapy, 2015, 13, 1293-1305.	1.5	13
136	Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography. Journal of Interventional Cardiology, 2016, 29, 168-178.	1.2	13
137	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. Journal of Thrombosis and Haemostasis, 2020, 18, 23-35.	3.8	13
138	Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. Journal of Thrombosis and Thrombolysis, 2021, 51, 902-904.	2.1	13
139	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized clinical trials. Cardiology Journal, 2012, 19, 230-242.	1.2	13
140	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. Current Treatment Options in Cardiovascular Medicine, 2009, 11, 22-32.	0.9	12
141	Thienopyridine efficacy and cigarette smoking status. American Heart Journal, 2013, 165, 693-703.	2.7	12
142	Unravelling the Smokers’ Paradox: Cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y12 inhibitors. Thrombosis and Haemostasis, 2014, 111, 1187-1190.	3.4	12
143	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCElerrated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by) Tj ETQq 1170.784314 rgBT O Journal of Cardiology, 2015, 190, 370-375.	1.7	12
144	P2Y12receptor inhibitors for secondary prevention of ischemic stroke. Expert Opinion on Pharmacotherapy, 2015, 16, 1149-1165.	1.8	12

#	ARTICLE	IF	CITATIONS
145	Antithrombotic Strategies and Device Thrombosis. <i>Cardiology Clinics</i> , 2018, 36, 541-550.	2.2	12
146	The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 969-981.	2.1	12
147	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. <i>Anesthesiology</i> , 2020, 133, 1263-1276.	2.5	12
148	A Novel Method of Studying Wound Healing. <i>Journal of Surgical Research</i> , 2001, 98, 16-20.	1.6	11
149	Modulation of Growth Factor and Cytokine Expression by Nitric Oxide During Rat Colon Anastomotic Healing. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 393-399.	1.7	11
150	Delivery of Glycoprotein IIb/IIIa Inhibitor Therapy for Percutaneous Coronary Intervention. <i>Circulation</i> , 2010, 121, 739-741.	1.6	11
151	Pharmacodynamic Effect of Cilostazol Plus Standard Clopidogrel Versus Double-Dose Clopidogrel in Patients With Type 2 Diabetes Undergoing Percutaneous Coronary Intervention. <i>Diabetes Care</i> , 2012, 35, 2194-2197.	8.6	11
152	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , 2014, 112, 323-331.	3.4	11
153	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. <i>Current Medical Research and Opinion</i> , 2017, 33, 1979-1984.	1.9	11
154	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 469-476.	2.1	11
155	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1131-1140.	3.4	11
156	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition. <i>Circulation</i> , 2020, 142, 1305-1307.	1.6	11
157	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , 2021, 32, 544-549.	1.0	11
158	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 957-970.	3.2	11
159	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1365-1370.	2.3	10
160	Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. <i>Canadian Journal of Cardiology</i> , 2016, 32, 724-725.	1.7	10
161	Selection of P2Y ₁₂ Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 460-470.	3.1	10
162	Meta-Analysis of the Usefulness of Therapeutic Hypothermia After Cardiac Arrest. <i>American Journal of Cardiology</i> , 2020, 133, 48-53.	1.6	10

#	ARTICLE	IF	CITATIONS
163	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , 2020, 16, 373-384.	1.2	10
164	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 484-498.	2.1	10
165	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 449-456.	3.4	10
166	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 992-998.	2.1	10
167	Smoking and cardiovascular diseases – is there more paradox than expected?. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 700-706.	0.4	10
168	Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , 2021, 6, 749-761.	4.1	10
169	Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 363.	2.1	10
170	Response variability and the role of platelet function testing. <i>Journal of Invasive Cardiology</i> , 2009, 21, 172-8.	0.4	10
171	Differential Cytokine Expression in Skin Graft Healing in Inducible Nitric Oxide Synthase Knockout Mice. <i>Plastic and Reconstructive Surgery</i> , 2001, 108, 1251-1259.	1.4	9
172	Acceptance of High Platelet Reactivity as a Risk Factor. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1008-1010.	2.9	9
173	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 233.	2.5	9
174	Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 12-20.	3.4	9
175	Importance of potent P2Y ₁₂ receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1771-1796.	1.8	9
176	The Clopidogrel-Statin Interaction. <i>Circulation Journal</i> , 2014, 78, 592-594.	1.6	9
177	Oxidized Low-Density Lipoprotein- β 2-Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016, 118, 673-678.	1.6	9
178	Wound fluid inhibits wound fibroblast nitric oxide synthesis. <i>Journal of Surgical Research</i> , 2004, 122, 43-48.	1.6	8
179	Platelet Function Testing Before CABG is Recommended in the Guidelines: But Do We Have Enough Evidence?. <i>Journal of Interventional Cardiology</i> , 2015, 28, 233-235.	1.2	8
180	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 223-233.	2.1	8

#	ARTICLE	IF	CITATIONS
181	Investigational drugs in phase II clinical trials for acute coronary syndromes. Expert Opinion on Investigational Drugs, 2020, 29, 33-47.	4.1	8
182	Immunity to thrombotic events is achievable if we stop the guessing game: Is this the major hidden message from GRAVITAS?. Thrombosis and Haemostasis, 2011, 106, 263-264.	3.4	7
183	The Dogged Search for Cryptic Effects of Ticagrelor. Circulation, 2016, 134, 1720-1723.	1.6	7
184	Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. Journal of Thrombosis and Thrombolysis, 2018, 45, 18-26.	2.1	7
185	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. Expert Review of Cardiovascular Therapy, 2018, 16, 419-429.	1.5	7
186	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. Progress in Cardiovascular Diseases, 2020, 63, 243-248.	3.1	7
187	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. Cardiology Journal, 2020, 27, 661-676.	1.2	7
188	Cutaneous Clopidogrel Hypersensitivity. Journal of the American College of Cardiology, 2011, 58, 1455-1456.	2.8	6
189	Further Ex Vivo Evidence Supporting Higher Aspirin Dosing in Patients With Coronary Artery Disease and Diabetes. Circulation: Cardiovascular Interventions, 2011, 4, 118-120.	3.9	6
190	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. American Heart Journal, 2013, 165, 176-182.	2.7	6
191	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. Expert Review of Cardiovascular Therapy, 2013, 11, 1259-1267.	1.5	6
192	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. Thrombosis and Haemostasis, 2014, 112, 1198-1208.	3.4	6
193	State of the art: Oral antiplatelet therapy. JRSM Cardiovascular Disease, 2016, 5, 204800401665251.	0.7	6
194	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. Expert Opinion on Pharmacotherapy, 2017, 18, 123-131.	1.8	6
195	HDL3-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. Cardiovascular Revascularization Medicine, 2019, 20, 1001-1006.	0.8	6
196	Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation. Journal of Thrombosis and Thrombolysis, 2021, 51, 260-264.	2.1	6
197	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. Platelets, 2022, 33, 520-530.	2.3	6
198	Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography. TH Open, 2021, 05, e570-e576.	1.4	6

#	ARTICLE	IF	CITATIONS
199	Point-of-Care Platelet Function Analysis. Journal of the American College of Cardiology, 2009, 53, 857-859.	2.8	5
200	Cilostazol to Overcome High On-Treatment Platelet Reactivity in Korean Patients Treated With Clopidogrel and Calcium-Channel Blocker. Circulation Journal, 2011, 75, 2534-2536.	1.6	5
201	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. Expert Review of Clinical Pharmacology, 2014, 7, 645-653.	3.1	5
202	The enigmatic search for optimal DAPT duration. European Heart Journal, 2014, 35, 951-954.	2.2	5
203	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: The results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. International Journal of Cardiology, 2014, 174, 129-132.	1.7	5
204	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. Journal of Thrombosis and Thrombolysis, 2016, 41, 394-403.	2.1	5
205	Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma. European Heart Journal, 2016, 37, 1143-1144.	2.2	5
206	HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm. European Heart Journal, 2017, 38, ehv630.	2.2	5
207	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. Atherosclerosis, 2018, 268, 55-62.	0.8	5
208	Cangrelor for the treatment of patients with Arterial Thrombosis. Expert Opinion on Pharmacotherapy, 2018, 19, 1389-1398.	1.8	5
209	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. Journal of Clinical Medicine, 2021, 10, 2720.	2.4	5
210	Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention. JACC Asia, 2022, 2, 323-337.	1.5	5
211	Antiplatelet effects of aspirin with phytosterols: Comparison with non-enteric coated aspirin alone. Thrombosis Research, 2010, 126, 384-385.	1.7	4
212	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review of Cardiovascular Therapy, 2013, 11, 1029-1049.	1.5	4
213	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. Expert Review of Cardiovascular Therapy, 2013, 11, 1547-1556.	1.5	4
214	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. Future Cardiology, 2013, 9, 785-797.	1.2	4
215	Pharmacodynamic Effects of Cilostazol Versus Clopidogrel in Stented Patients under Proton Pump Inhibitor Co-administration: The ACCEL-PARAZOL Study. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1121-1139.	2.0	4
216	What have we learned from the ANTARCTIC trial?. Nature Reviews Cardiology, 2016, 13, 639-640.	13.7	4

#	ARTICLE	IF	CITATIONS
217	More Evidence for Non-P2Y ₁₂ -Mediated Effects of Ticagrelor. JACC: Cardiovascular Interventions, 2017, 10, 1659-1661.	2.9	4
218	Pharmacodynamic effects of a new fixed-dose clopidogrel+aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. Platelets, 2017, 28, 187-193.	2.3	4
219	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. Future Cardiology, 2020, 16, 69-75.	1.2	4
220	Platelet Function Measurement in Elective Percutaneous Coronary Intervention Patients. JACC: Cardiovascular Interventions, 2012, 5, 290-292.	2.9	3
221	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. Interventional Cardiology Clinics, 2012, 1, 223-230.	0.4	3
222	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. International Journal of Cardiology, 2013, 168, 427-435.	1.7	3
223	Platelet Activation and Pneumonia. Journal of the American College of Cardiology, 2015, 65, 1492-1493.	2.8	3
224	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. Expert Review of Cardiovascular Therapy, 2016, 14, 1361-1370.	1.5	3
225	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. Expert Review of Cardiovascular Therapy, 2016, 14, 779-791.	1.5	3
226	The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy. European Heart Journal, 2019, 40, 2441-2443.	2.2	3
227	Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score. Blood, 2015, 126, 3445-3445.	1.4	3
228	Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can the Thrombin Pathway Be a New Target for Therapy?. Korean Circulation Journal, 2020, 50, 817.	1.9	3
229	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. Cardiology Journal, 2021, , .	1.2	3
230	Clinical applications of antiplatelet therapy. Reviews in Cardiovascular Medicine, 2006, 7, 130-46; quiz 148-9.	1.4	3
231	The Worry About Clopidogrel Nonresponsiveness. JACC: Cardiovascular Interventions, 2009, 2, 1102-1104.	2.9	2
232	The next 10 years in personalized medicine in cardiology. Expert Review of Cardiovascular Therapy, 2013, 11, 933-935.	1.5	2
233	Inhibited and Uninhibited Platelet Deposition Within a Thrombus. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2081-2082.	2.4	2
234	CardioPulse ArticlesThe future of percutaneous coronary interventionsPlatelet inhibitors and their differencesTriple therapy for percutaneous coronary intervention in atrial fibrillation: a nightmareDifferent bleeding scores and which one should we use?Thrombus aspiration does not improve 12-month outcomesElevating endovascular aneurysm repair to new heights<i>European Heart Journal</i>annual awards of appreciationMore dual anti-platelet therapy data favoured at European Society of Cardiology Congress Londo. European Heart Journal, 2016, 37, 322-334.	2.2	2

#	ARTICLE	IF	CITATIONS
235	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2019, 119, 264-273.	3.4	2
236	An Ex Vivo Study to Evaluate the Effect of Tegasero on Platelet Activation and Aggregation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 40-50.	2.0	2
237	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 272-280.	2.1	2
238	Antiplatelet treatment of cardiovascular disease: a translational research perspective. <i>Polish Archives of Internal Medicine</i> , 2008, 118, 289-297.	0.4	2
239	Antiplatelet therapy beyond 2012: role of personalized medicine. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 298-305.	0.4	2
240	Further evidence for the use of aspirin in COVID-19. <i>International Journal of Cardiology</i> , 2021, 346, 107-108.	1.7	2
241	Antiplatelet therapy beyond 2012: role of personalized medicine. , 2012, 122, 298-305.		2
242	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. <i>Interventional Cardiology Clinics</i> , 2013, 2, 607-614.	0.4	1
243	Triple Antithrombotic Therapy With Prasugrel in the Stented Patient. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2067-2069.	2.8	1
244	Letter by Gurbel et al Regarding Article, "Administration of a Loading Dose Has No Additive Effect on Platelet Aggregation During the Switch From Ongoing Clopidogrel Treatment to Ticagrelor in Patients With Acute Coronary Syndrome" • <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 273-273.	3.9	1
245	Personalized Antiplatelet Therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 480-487.	0.6	1
246	PRASFIT-ACS: Important Evidence Against a "One-Guideline-Fits-All-Races" Approach to Antiplatelet Therapy. <i>Circulation Journal</i> , 2014, 78, 2563.	1.6	1
247	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. <i>Platelets</i> , 2015, 26, 608-609.	2.3	1
248	Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 275-278.	4.0	1
249	POINT-OF-CARE CYP2C19 GENOTYPE GUIDED ANTIPLATELET THERAPY IN CARDIAC CATHETERIZATION LABORATORY AND CLINICAL OUTCOMES AFTER PCI. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1329.	2.8	1
250	Pharmacogenetic considerations in antiplatelet therapy. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 235-238.	0.7	1
251	Assessing platelet reactivity after drug eluting stent implantation: state of the art. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 17-24.	1.5	1
252	IS LOW DOSE ASPIRIN EFFECTIVE IN REDUCING IN-HOSPITAL CLINICAL OUTCOMES IN PATIENTS WITH COVID-19?. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3083.	2.8	1

#	ARTICLE	IF	CITATIONS
253	Antiplatelet Resistance—Fact or Myth?. The American Heart Hospital Journal, 2009, 7, 50.	0.2	1
254	Temporal Variability of Platelet Reactivity Phenotype: Another Barrier to Personalized Antiplatelet Strategy Guided by Platelet Function Testing. Korean Circulation Journal, 2019, 49, 1062.	1.9	1
255	In vitro evidence for the role of cytokine storm in the generation of stent thrombosis in COVID -19 patients. Cardiovascular Revascularization Medicine, 2021, 35, 139-139.	0.8	1
256	Current options in oral antiplatelet strategies during percutaneous coronary interventions. Reviews in Cardiovascular Medicine, 2011, 12 Suppl 1, S4-13.	1.4	1
257	Diagnostics for Aspirin Resistance. Molecular Diagnosis and Therapy, 2008, 12, 55-56.	3.8	0
258	Thienopyridine Response Variability and Resistance. , 0, , 77-93.		0
259	Role of ticagrelor in the treatment of coronary artery disease. Clinical Investigation, 2011, 1, 429-437.	0.0	0
260	Ticagrelor in the treatment of coronary artery disease patients. Clinical Practice (London, England), 2012, 9, 373-390.	0.1	0
261	Caution in interpreting the findings from small observational studies. International Journal of Cardiology, 2012, 160, 71.	1.7	0
262	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y ₁₂ receptor inhibitors. Expert Review of Cardiovascular Therapy, 2012, 10, 1011-1022.	1.5	0
263	TCT-716 First Simultaneous Assessment of the Effects of Fish Oil Supplementation on Lipid and Thrombogenicity Profiles. Journal of the American College of Cardiology, 2012, 60, B208-B209.	2.8	0
264	AS-302 Influence of Platelet Reactivity and Inflammation on Peri-procedural Myonecrosis in East Asian Patients Undergoing Elective Percutaneous Coronary Intervention. American Journal of Cardiology, 2012, 109, S14.	1.6	0
265	P2Y ₁₂ Receptor Blockade and Myocardial Perfusion. JACC: Cardiovascular Interventions, 2013, 6, 684-686.	2.9	0
266	A Bigger Look Into the “Therapeutic Window” of Platelet Reactivity to Adenosine Diphosphate. JACC: Cardiovascular Interventions, 2015, 8, 1988-1989.	2.9	0
267	To stop or continue aspirin before aortocoronary bypass operations—do we have enough evidence to adequately guide us?. Journal of Thoracic Disease, 2016, 8, E578-E580.	1.4	0
268	SERIAL ASSESSMENT OF THROMBOGENICITY AND HEMODYNAMICS IN PATIENTS WITH TYPE II DIABETES OBSERVED IN A CLINICAL RESEARCH UNIT: EVIDENCE FOR CIRCADIAN CHANGES IN CLOT FORMATION. Journal of the American College of Cardiology, 2017, 69, 93.	2.8	0
269	HDL3: A MARKER OF CORONARY ARTERY DISEASE SEVERITY AND INFLAMMATION IN PATIENTS ON STATIN THERAPY. Journal of the American College of Cardiology, 2017, 69, 149.	2.8	0
270	ASSESSMENT OF THROMBOGENICITY AND ANTITHROMBOTIC DRUG RESPONSE AT THE BEDSIDE IN PATIENTS PRESENTING WITH ISCHEMIC STROKE, TIA OR INTRACRANIAL HEMORRHAGE. Journal of the American College of Cardiology, 2017, 69, 148.	2.8	0

#	ARTICLE	IF	CITATIONS
271	The potential of genotype-guided antiplatelet therapy: promises and challenges. Expert Review of Precision Medicine and Drug Development, 2018, 3, 371-377.	0.7	0
272	Antithrombotic treatment strategies after PCI. Lancet, The, 2020, 395, 866-867.	13.7	0
273	Is a personalized pharmacotherapeutic approach closed for acute coronary syndrome?. Expert Opinion on Pharmacotherapy, 2021, 22, 527-529.	1.8	0
274	Is meta-analysis the optimal method to decide the duration of antiplatelet therapy in diabetic patients treated with drug-eluting stenting?. Polish Archives of Internal Medicine, 2021, 131, 776-778.	0.4	0
275	In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. Kardiologia Polska, 2019, 77, 817-819.	0.6	0
276	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0